P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

November 2013

Features

Overview of Omega-3 Fatty Acid Therapies

Products containing omega-3 fatty acids, such as krill oil and fish oils, have been effective in lowering triglyceride levels. Although no data have suggested that the low-density lipoprotein-cholesterol (LDL-C) increases associated with some omega-3 fatty acid formulations lead to adverse outcomes, these elevations in LDL-C levels may compromise the achievement of lipid targets. Thus, there is a need for agents that can lower triglyceride levels without increasing LDL-C levels.
J. Chris Bradberry, PharmD; and Daniel E. Hilleman, PharmD

Activated Prothrombin Complex Concentrates for the Reversal of Anticoagulant-Associated Coagulopathy

Managing hemorrhaging after the use of warfarin and other anticoagulants is challenging. Although an FDA-approved product, FEIBA, has been used as an offlabel anticoagulant-reversal agent, the potential risks of thrombosis associated with activated prothrombin complex concentrates must be carefully weighed.
Nadia I. Awad, PharmD; and Craig Cocchio, PharmD, BCPS

Qualified Insurance Plans on Health Exchanges May Reduce Drug Availability

Hospital Pharmacies Could Face New Pressures

With the Patient Protection and Affordable Care Act going into effect in 2014, hospitals are scrambling to ensure that their formularies meet federal standards.
Stephen Barlas

Meeting Highlights

2013 European Cancer Congress

Therapies for breast cancer, melanoma, lung cancer, and neuroendocrine tumors
Walter Alexander

Departments

Prescription: Washington

FDA Requires New Labeling for Some Opioids

Modest Changes Walk Narrow Political Line

Stricter labeling requirements for ER and LA opioids might not be enough.
Stephen Barlas

Medication Errors

Perilous Infection-Control Practices with Needles, Syringes, and Vials

Vigorous Monitoring Is Crucial

Avoiding dangerous lapses in infection-control practices
Matthew Grissinger, RPh, FASCP

Drug Forecast

Canagliflozin (Invokana), a Novel Oral Agent For Type-2 Diabetes

Sheila Sarnoski-Brocavich, BS, MS, PharmD, BCACP, CGP; and Olga Hilas, PharmD, MPH, BCPS, CGP

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates

Pharmaceutical Approval Update

Vortioxetine (Brintellix) for major depressive disorder; ustekinumab (Stelara) for psoriatic arthritis; and dabrafenib mesylate (Tafinlar) for metastatic melanoma
Marvin M. Goldenberg, PhD, RPh, MS